We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Mereo BioPharma
Setrusumab partnered with UltragenyxNexstim
Planning the next phase of growthMereo BioPharma
Targeting TIGIT thoughtfullyRedx Pharma
£25.5m placing extends runway to end-2022Nexstim
€0.9m prototype research project signedHutchison China MediTech
Canada Pension Plan invests $100m at $30 per ADSScancell
Redmile funding releases the brakesAllergy Therapeutics
Innovative G309 exploratory grass trial startsFutura Medical
MED3000: FDA details the scope of confirmatory studyMereo BioPharma
H120 results and corporate review